Regeneron Pharmaceuticals, Inc. $REGN Stock Position Decreased by Candriam S.C.A.

Candriam S.C.A. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 173,146 shares of the biopharmaceutical company’s stock after selling 22,528 shares during the quarter. Candriam S.C.A. owned about 0.17% of Regeneron Pharmaceuticals worth $131,771,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Ethic Inc. lifted its position in Regeneron Pharmaceuticals by 3.1% in the 3rd quarter. Ethic Inc. now owns 16,570 shares of the biopharmaceutical company’s stock valued at $12,564,000 after acquiring an additional 501 shares in the last quarter. Parallel Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 8.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,158 shares of the biopharmaceutical company’s stock worth $878,000 after purchasing an additional 95 shares in the last quarter. Abacus Wealth Partners LLC increased its holdings in Regeneron Pharmaceuticals by 5.4% during the 3rd quarter. Abacus Wealth Partners LLC now owns 722 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 37 shares in the last quarter. United Advisor Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 12.2% in the 3rd quarter. United Advisor Group LLC now owns 376 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 41 shares during the period. Finally, Plancorp LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 2.3% in the third quarter. Plancorp LLC now owns 928 shares of the biopharmaceutical company’s stock valued at $704,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 4,466 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares in the company, valued at $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the sale, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 28,228 shares of company stock worth $25,985,950 in the last 90 days. 6.97% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Robert W. Baird increased their price objective on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a report on Monday, November 2nd. Finally, Citigroup increased their target price on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals Stock Up 0.2%

NASDAQ:REGN opened at $904.35 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The firm has a market capitalization of $93.11 billion, a price-to-earnings ratio of 19.97, a price-to-earnings-growth ratio of 1.20 and a beta of 0.10. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average price is $804.38 and its two-hundred day moving average price is $742.81.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period last year, the business earned $11.83 earnings per share. The firm’s revenue was up 36.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.